# Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults

> **NCT03646799** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 36 (estimated)

## Conditions studied

- Type II Diabetes

## Interventions

- **DRUG:** CKD-387
- **DRUG:** D484

## Key facts

- **NCT ID:** NCT03646799
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-30
- **Primary completion:** 2018-09-09
- **Final completion:** 2018-09-14
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03646799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03646799, "Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03646799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*